To conduct a preliminary experimental evaluation of the potential efficacy of Flexyx Neurotherapy System (FNS), an innovative electroencephalography (EEG)-based therapy used clinically in the treatment of traumatic brain injury (TBI).
Twelve people aged 21 to 53 who had experienced mild to moderately severe closed head injury at least 12 months previously and who reported substantial cognitive difficulties after injury, which interfered with their functioning.
Participants were randomly assigned to an immediate treatment group or a wait-list control group and received 25 sessions of FNS treatment. They were assessed at pretreatment, posttreatment, and follow-up with standardized neuropsychological and mood measures.
Comparison of the two groups on outcome measures indicated improvement after treatment for participants' reports of depression, fatigue, and other problematic symptoms, as well as for some measures of cognitive functioning. Most participants experienced meaningful improvement in occupational and social functioning.
On the basis of these results, FNS appears to be a promising new therapy for TBI and merits more extensive evaluation.
Director of Research (Shiflett)
Research Assistant (Matheis)
*Kessler Medical Rehabilitation Research and Education Corporation, West Orange, New Jersey
†Center for Health and Healing, Beth Israel Medical Center, New York, New York
‡Neurotherapy Center of Washington, Chevy Chase, Maryland
§Flexyx, LLC, Walnut Creek, California.
Address correspondence and requests for reprints to Nancy E. Schoenberger, PhD, P.O. Box 18082, Memphis, TN 38181. Telephone: (901) 332-0781; e-mail: email@example.com.
This research was supported by NIH grant U24 HD32994 from the National Center for Complementary and Alternative Medicine (NCCAM) and the National Center for Medical Rehabilitation Research (NCMRR).
The authors gratefully acknowledge the invaluable feedback provided by the men and women who participated in this study. Their collaboration was essential to the success of the project.